Internal Neuromodulation Devices Market Report 2025

The internal neuromodulation devices market size has grown strongly in recent years. It will grow from $2.59 billion in 2024 to $2.77 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to chronic pain management, aging population, clinical research and trials, neurological disorders prevalence, patient awareness and acceptance.

The internal neuromodulation devices market size is expected to see strong growth in the next few years. It will grow to $3.94 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to personalized medicine trends, rising healthcare expenditure, collaborations and partnerships, patient outcomes and real-world evidence, regulatory landscape changes. Major trends in the forecast period include miniaturization and implantable technology, wireless connectivity and remote monitoring, expanded applications for neuromodulation, closed-loop systems for precise modulation, focus on patient-centric design.

The rising incidence of neurological diseases is anticipated to drive growth in the internal neuromodulation devices market. Neurological diseases encompass a wide range of disorders that impact the nervous system, including the brain, spinal cord, and peripheral nerves. Internal neuromodulation devices are used to treat neurological and psychiatric conditions by delivering targeted electrical stimulation to specific parts of the nervous system, helping to alleviate symptoms like chronic pain, movement disorders, and mood disorders. These devices can enhance patients' quality of life by reducing symptoms, making it easier for them to carry out daily tasks. For example, in April 2023, the National Library of Medicine, a U.S.-based biomedical library, reported that 6.7 million Americans are living with Alzheimer’s, a number projected to reach 13.8 million by 2060. Additionally, in May 2022, the House of Lords Library in the UK reported that as of January 31, 2022, there were 1,638 full-time equivalent staff in England’s neurology workforce, up from 1,562 in 2021 and 1,468 in 2020. Consequently, the increasing prevalence of neurological diseases is fueling the expansion of the internal neuromodulation devices market.

The rising incidence of brain cancers is anticipated to fuel the expansion of the internal neuromodulation devices market. Brain cancer, a diverse group of tumors originating in the brain or spinal cord, poses complex challenges for understanding and treatment. Internal neuromodulation devices emerge as a promising therapeutic solution for various brain disorders, delivering electrical stimulation or other forms of energy directly to specific brain regions to modulate neuronal activity and induce therapeutic effects. In 2022, the National Brain Tumor Society reported an expected diagnosis of brain tumors in approximately 94,390 Americans, with an estimated 18,990 deaths from malignant brain tumors in 2023. Thus, the growing incidence of brain cancers serves as a catalyst for the growth of the internal neuromodulation devices market.

A prominent trend gaining traction in the internal neuromodulation devices market is product innovation. Major companies in this segment are actively engaged in developing new technologies to maintain their market positions. For instance, in March 2023, Ireland-based medical equipment manufacturer Neuromod Device Ltd. announced that its Lenire system had received De Novo clearance from the US Food and Drug Administration (FDA). The Lenire system employs a combination of sound stimulation and tongue stimulation to treat tinnitus, a neurological disorder characterized by ringing in the ears. This innovative system uses a dual-pronged approach to neurostimulation, utilizing Bluetooth headphones to play unique sounds stimulating the auditory nerve, while Neuromod's Tonguetip device transmits moderate electrical stimulation to the tongue's surface. This technology provides otolaryngologists with an innovative tool to recommend to patients experiencing a moderately negative impact on their lives due to tinnitus.

Major companies in the internal neuromodulation devices market are concentrating on developing technological innovations, including digital health apps, to gain a competitive edge. Digital health apps are software applications designed to deliver health-related services and information to users on mobile devices. For example, in July 2022, US-based medical device provider Abbott Laboratories launched the NeuroSphere Virtual Clinic, a groundbreaking technology allowing patients with Abbott's neurostimulation devices to remotely communicate with doctors. This feature enables patients to ensure proper settings, functionality, and receive new treatment settings via secure in-app video chat and integrated remote programming. The platform provides real-time data to physicians about patients' device usage and pain levels.

In March 2022, US-based medical equipment manufacturer Electromedical Products International (EPI) acquired Pulvinar Neuro for an undisclosed amount. Through this acquisition, Pulvinar Neuro gains enhanced capabilities for promoting its patented technologies, such as transcranial alternating current stimulation (tACS). Additionally, the acquisition enhances its cloud-enabled digital treatments for mental and neurological conditions and customized feedback stimulation. Pulvinar Neuro is a US-based medical technology company specializing in deep brain stimulation (DBS) systems for treating neurological and psychiatric disorders.

Major companies operating in the internal neuromodulation devices market include Medtronic plc, Boston Scientific Corporation, BioControl Medical Ltd., Aleva Neurotherapeutics SA, Bioness Inc., Uroplasty Inc., Abbott Laboratories, EnteroMedics Inc., LivaNova plc, NeuroPace Inc., Synapse Biomedical Inc., Soterix Medical Inc., Neuros Medical Inc., Nevro Corp., Nuvectra Corporation, Stimwave Technologies Incorporated, SPR Therapeutics, Axonics Modulation Technologies Inc., Saluda Medical Pty Limited, MicroTransponder Inc., EndoStim Inc., NeuroMetrix Inc., Second Sight Medical Products Inc., Neurotech International Limited, Neuronix Ltd., Neuronoff Inc.

North America was the largest region in the internal neuromodulation devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global internal neuromodulation devices market report during the forecast period. The regions covered in the internal neuromodulation devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the internal neuromodulation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Internal neuromodulation devices are a category of medical devices that are surgically implanted inside the body to deliver electrical stimulation to specific areas of the nervous system, offering relief for various neurological and psychiatric conditions.

The primary types of internal neuromodulation devices include spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and gastric neurostimulators. These devices utilize different technologies, encompassing both internal and external neuromodulation, along with biomaterials such as metallic biomaterials, polymeric biomaterials, and ceramic biomaterials. They find applications in treating conditions such as failed back surgery syndrome, Parkinson's disease, urinary incontinence, epilepsy, and gastroparesis. The end-users of these devices span hospitals, clinics, home healthcare, and community healthcare.

The internal neuromodulation devices market research report is one of a series of new reports that provides internal neuromodulation devices market statistics, including internal neuromodulation devices industry global market size, regional shares, competitors with a internal neuromodulation devices market share, detailed internal neuromodulation devices market segments, market trends and opportunities, and any further data you may need to thrive in the internal neuromodulation devices industry. This internal neuromodulation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The internal neuromodulation devices market consists of sales of electrodes, leads, receivers, and others. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.